WallStSmart

Merck & Company Inc (MRK)vsRxsight Inc (RXST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 51492% more annual revenue ($65.77B vs $127.48M). MRK leads profitability with a 13.6% profit margin vs -36.6%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

RXST

Avoid

34

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 6.7Quality: 8.0
Piotroski: 2/9Altman Z: 2.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-62.3%)

Margin of Safety

-62.3%

Fair Value

$81.23

Current Price

$128.06

$46.83 premium

UndervaluedFair: $81.23Overvalued
RXSTUndervalued (+71.3%)

Margin of Safety

+71.3%

Fair Value

$27.94

Current Price

$6.25

$21.69 discount

UndervaluedFair: $27.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$307.25B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

RXST2 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
35.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RXST4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$253.76M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-17.4%2/10

ROE of -17.4% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : RXST

The strongest argument for RXST centers on Price/Book, Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : RXST

The primary concerns for RXST are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

MRK profiles as a value stock while RXST is a turnaround play — different risk/reward profiles.

RXST carries more volatility with a beta of 1.15 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 34/100). RXST offers better value entry with a 71.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Rxsight Inc

HEALTHCARE · MEDICAL DEVICES · USA

Rxsight Inc. is a cutting-edge healthcare technology company dedicated to transforming vision correction through advanced diagnostic and surgical solutions in refractive eye surgery. By integrating proprietary software with precision laser systems, Rxsight aims to significantly improve patient outcomes and enhance the quality of life for those seeking vision correction. The company boasts a robust intellectual property portfolio and strategic collaborations that position it favorably within the growing ophthalmic market. Committed to innovation and operational excellence, Rxsight is poised to drive substantial advancements in eye care, reflecting its potential for sustained growth and impact in the sector.

Want to dig deeper into these stocks?